alterations,drugs,approvedIndications,level,fdaLevel,levelAssociatedCancerType,levelExcludedCancerTypes,pmids,abstracts,description
['Amplification'],"[{'ncitCode': 'C174208', 'drugName': 'Lirafugratinib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}",[],"['37270847', '38300868']","[{'link': 'https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R', 'abstract': 'Borad et al. Abstract# 4009, ASCO 2023.'}]","Lirafugratinib is an orally available, small molecule FGFR2 tyrosine kinase inhibitor. There are promising laboratory and anecdotal clinical data to support use of lirafugratinib in patients with FGFR2-amplified solid tumors. In the Phase I/II ReFocus (NCT04526106) trial of lirafugratinib in patients with FGFR2-altered (fusions, amplifications and mutations) CCA who are either FGFRi-naïve (n=10) or FGFRi-pretreated (n=4), the FGFRi-naïve cohort achieved three partial responses (PR) (FGFR2 R678G, C383R and H167_N173del) with a disease control rate of 70% and the FGFRi-pretreated cohort achieved one PR, two stable disease responses and one progressive disease response (Abstract: Borad et al. Abstract# 4009, ASCO 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.4009?af=R). Preclinical studies of FGFR2-amplified gastric cancer cell lines and models demonstrates sensitivity to lirafugratinib as measured by inhibition of FGFR2 phosphorylation (PMID: 37270847, 38300868)."
